Mirum Pharmaceuticals is projected to report Q3 2026 revenue of $178.07 million and an EPS loss of $0.53, with shares currently trading at $86.00 relative to a bullish analyst price target of $153.43.
The primary focus for investors is the sustained commercial growth of LIVMARLI and its potential label expansion following the successful Phase 3 EXPAND trial results for ultra-rare cholestatic liver diseases.
The company has demonstrated significant momentum, recently posting a 46% year-over-year increase in LIVMARLI sales while advancing its late-stage pipeline candidates, volixibat and brelovitug. Analysts remain optimistic about Mirum's trajectory as it moves toward filing for expanded indications and consolidating its leadership in the rare liver disease market.